Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 1,230,000 shares, a drop of 6.1% from the November 15th total of 1,310,000 shares. Currently, 3.8% of the company's stock are short sold. Based on an average daily volume of 712,600 shares, the days-to-cover ratio is currently 1.7 days.
Werewolf Therapeutics Price Performance
NASDAQ HOWL traded down $0.02 during mid-day trading on Tuesday, hitting $1.64. The stock had a trading volume of 314,007 shares, compared to its average volume of 381,636. Werewolf Therapeutics has a 52-week low of $1.58 and a 52-week high of $8.19. The company has a market cap of $73.08 million, a price-to-earnings ratio of -1.07 and a beta of 0.30. The company has a 50 day simple moving average of $2.13 and a 200 day simple moving average of $2.32. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.
Hedge Funds Weigh In On Werewolf Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOWL. SG Americas Securities LLC acquired a new position in Werewolf Therapeutics in the 3rd quarter valued at about $29,000. Point72 DIFC Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter worth about $34,000. XTX Topco Ltd acquired a new position in shares of Werewolf Therapeutics during the 3rd quarter valued at about $45,000. Rhumbline Advisers acquired a new stake in shares of Werewolf Therapeutics in the second quarter worth approximately $79,000. Finally, American Century Companies Inc. grew its holdings in Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company's stock valued at $92,000 after purchasing an additional 12,656 shares during the period. Institutional investors and hedge funds own 64.84% of the company's stock.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.
Check Out Our Latest Stock Analysis on Werewolf Therapeutics
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
See Also
Before you consider Werewolf Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.
While Werewolf Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
